Danaher Corporation (DHR NYSE) stock market data APIs
$202.8067
3.81(1.9%)
as of July 11, 2025
Try our APIs with
free plan!
Danaher Corporation Financial Data Overview
Price chart is built with
Anychart
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a partnership with AstraZeneca PLC to develop and commercialize diagnostic tools and tests. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and
Prev. Close
202.8067
Open
206.6178
High
206.9982
Low
203.735
52 wk Range
170.7284-280.2229
Market Cap
146 605 M
P/E Ratio
39.6996
Shares Outstanding
716 M
Revenue
23 820 M
EPS
1.88
Dividends (Yield)
0.0065
Beta
0.799
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Danaher Corporation data using free add-ons & libraries
Get Danaher Corporation Fundamental Data
Danaher Corporation Fundamental data includes:
- Net Revenue: 23 820 M
- EBITDA: 7 464 M
- Earnings Per Share: 5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-22
- EPS/Forecast: 1.64
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Danaher Corporation News
New
Validea Detailed Fundamental Analysis - DHR
Below is Validea's guru fundamental report for DANAHER CORP (DHR). Of the 22 guru strategies we follow, DHR rates highest using our Small-Cap Growth Investor model based on the published strategy of ...
CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Liquid Handling Systems Market Insights Report 2025-2030 | Advancements in Microplate Reagent Dispensers, Transformation in Genomics, Importance in Drug Discovery & Development, Lab Automation
Company Logo The Liquid Handling Systems Market is anticipated to grow from USD 4.34 billion in 2024 to USD 6.75 billion by 2030, with a CAGR of 7.64%. Key drivers include the increased focus on lab ...
Goldman Sachs reiterates Conviction Buy on Baxter stock as new CEO appointed
Investing.com - Goldman Sachs has reiterated its Conviction Buy rating and $37.00 price target on Baxter International (NYSE:BAX), a $15.4 billion healthcare equipment manufacturer, following the comp...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
